Top 5 Most Read RNS's on Vox Markets for Thursday 1st September 2022
Episode 865, Sep 01, 2022, 06:38 AM
5. Mode Global Holdings #MODE Mode reaches 300 brands with Bitcoin Cashback
It is now offering Bitcoin Cashback to users from over 300 leading UK retailers, strengthening its vision of building a popular crypto reward wallet in the UK.
(Click here to read the RNS)
4. Argo Blockchain #ARB September 2022 Investor Conference Participation
The Company will participate in 3 investor conferences in September 2022.
(Click here to read the RNS)
3. Rambler Metals & Min #RMM Significance of Stope In-fill Drilling Program
Toby Bradbury, President and CEO, commented, "This infill drilling is improving the quality of our mining process and at the same time improving the overall quantity and quality of our mineral resources."
(Click here to read the RNS)
2. EQTEC #EQT Update on Deeside Project
Are in advanced discussions with a third party for the sale of the Project
(Click here to read the RNS)
1. Avacta Group #AVCT Phase I study of AVA6000 advances to fourth cohort
The first-in-human Phase I trial (ALS-6000-101) of AVA6000 Pro-doxorubicin will advance to the fourth dose cohort of patients following a positive review of the safety and tolerability data from the dosing of the third cohort.
(Click here to read the RNS)
It is now offering Bitcoin Cashback to users from over 300 leading UK retailers, strengthening its vision of building a popular crypto reward wallet in the UK.
(Click here to read the RNS)
4. Argo Blockchain #ARB September 2022 Investor Conference Participation
The Company will participate in 3 investor conferences in September 2022.
(Click here to read the RNS)
3. Rambler Metals & Min #RMM Significance of Stope In-fill Drilling Program
Toby Bradbury, President and CEO, commented, "This infill drilling is improving the quality of our mining process and at the same time improving the overall quantity and quality of our mineral resources."
(Click here to read the RNS)
2. EQTEC #EQT Update on Deeside Project
Are in advanced discussions with a third party for the sale of the Project
(Click here to read the RNS)
1. Avacta Group #AVCT Phase I study of AVA6000 advances to fourth cohort
The first-in-human Phase I trial (ALS-6000-101) of AVA6000 Pro-doxorubicin will advance to the fourth dose cohort of patients following a positive review of the safety and tolerability data from the dosing of the third cohort.
(Click here to read the RNS)